Cargando…
Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
Autores principales: | Li, Yiqun, Wang, Yanfeng, Li, Ning, Liang, Xinjun, Zhang, Shu, Fan, Qingxia, Yin, Xianli, Zhuang, Zhixiang, Liu, Yunpeng, Zhang, Jingdong, Kou, Xiaoge, Zhong, Haijun, Xu, Binghe, Huang, Jing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276316/ https://www.ncbi.nlm.nih.gov/pubmed/35730374 http://dx.doi.org/10.1097/CM9.0000000000002054 |
Ejemplares similares
-
HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
por: Song, Yan, et al.
Publicado: (2020) -
Focus on anticancer therapy-induced cardiotoxicity from the perspective of oncologists
por: Liu, Binliang, et al.
Publicado: (2022) -
Inflammatory biomarkers in assessing severity and prognosis of immune checkpoint inhibitor‐associated cardiotoxicity
por: Liang, Lin, et al.
Publicado: (2023) -
No evidence for cardiotoxicity of miltefosine()
por: Dorlo, Thomas P.C.
Publicado: (2022) -
No evidence for cardiotoxicity of miltefosine – Reply()
por: Barroso, Daniel Holanda, et al.
Publicado: (2022)